Search
Searching Goglides
Loading matching companies, research, topics, and discussions.
Searching Goglides
Loading matching companies, research, topics, and discussions.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
Showing public results only.
A Coverage Bootstrap ASML company evaluation covering the business model, EUV and DUV products, customers, moat, financial quality, export-control risk, valuation setup, and watchlist triggers.
Signed-in searches appear here after you use search.
Tag facets appear after tag usage counts are rebuilt.
SEC filings, financial facts, source resources, and Goglides workspace context for ASML Holding N.V..
OpenA Coverage Bootstrap NVIDIA company evaluation covering AI accelerators, CUDA, networking, data-center concentration, margins, export controls, valuation risk, and proof gates.
OpenAn ASML five-year double thesis focused on EUV scarcity, High-NA adoption, China/export-control risk, bookings visibility, and semiconductor capex cycles.
OpenASML's High-NA lithography story is about whether monopoly-like tools keep controlling the next chip node.
OpenAgios has FDA-approved mitapivat products, an early AQVESME thalassemia launch and more than $1.0B of cash and marketable securities. The diligence question is whether prescription growth and pipeline catalysts can outpace a quarterly expense base above $130M.
OpenACAD is no longer the kind of biotech where everything hangs on a single trial. The sharper question is whether NUPLAZID and DAYBUE can fund a third CNS franchise before concentration, payer pressure, and pipeline risk catch up.
OpenAlpha Cognition has an FDA-approved Alzheimer's pill, early long-term-care launch traction, two PBM agreements, and $66.0 million of year-end cash, but the story depends on ZUNVEYL turning bottle growth into repeat, reimbursed revenue before launch spending, s
OpenTag facets appear after tag usage counts are rebuilt.